We venture to Lyon, France to learn how Marc and his team fresh off a $28 million raise are setting the stage to dominate High Intensity Focused Ultrasound (HIFU) for prostate cancer. Read more

EDAP TMS, the global leader in robotic energy-based therapies, announces today that the company has selected Medical Technology Partners (MTP) and Argenta Advisors, two leading reimbursement consultancies, to further expand coverage, accelerate market access and secure future payment rates for the company’s Focal One high intensity focused ultrasound (HIFU) procedure in the US. The announcement follows the establishment of a Category 1 CPT code, and physician reimbursement for HIFU, that went into effect on January 1, 2021. Read more

Marc Oczachowski is Chairman of the Board and Chief Executive Officer of EDAP TMS, a high-tech medical company which develops, manufactures markets minimally invasive therapeutic ultrasound solutions for urology, tumor removal, localized prostate cancer, and infectious diseases. Read more

Positive 24 month interim results of French Urology Association (AFU) sponsored clinical trial study comparing HIFU to radical prostate surgery: results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP). Read more

EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold. Read more